TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03064217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Making impression at surgery
Description: Making impression at surgery
Study: NCT01503762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: mirror therapy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Classical rehabilitation techniques
Description: splinting, tendon gliding, active range of motion, activities of daliy living
Study: NCT02597244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Extraforaminotomy
Description: percutaneous dissecting of the lumbar extraforaminal and foraminal region with BS extraforamonotomy kit(BioSpine Co.,Ltd, Seoul, South Korea) under fluoroscopy
Study: NCT04129164

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VIB4920
Description: Intravenous Dose 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VIB4920
Description: Intravenous Dose 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB4920
Description: Intravenous Dose 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB4920
Description: Intravenous Dose 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous dose matched to VIB4920.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous dose matched to VIB4920.
Study: NCT00264147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: diclofenac
Description: Period II: Arm 2: diclofenac 75 mg tablet twice daily. 12 weeks of treatment.
Study: NCT04129164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous dose matched to VIB4920.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous dose matched to VIB4920.
Study: NCT01316575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nCPAP
Description: The experimental group will receive nasal CPAP at 10cmH20 for one hour in the Post Anesthetic Care Unit.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Flow Oxygen
Description: The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
Study: NCT01869504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon-tipped intercostal drain
Description: Ballooned intercostal drain for pleural effusion, inserted using local anaesthetic and ultrasound guidance.
Study: NCT00827476

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ovarian transplantation
Description: ovarian xenotransplantation or in vitro culture
Study: NCT00734357

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood work
Description: Prior to having the clinically scheduled CT examination the subject will have blood work drawn. This blood work will give the investigators a baseline value of the basic kidney function of the subject. They will then have blood work done again at 2 days and again at 3 days following the CT examination. Some patients, based on their blood work obtained at 2 and 3 days after the CT examination, will be asked to have blood work performed at 7 days after their CT examination.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood work
Description: Prior to having the clinically scheduled CT examination the subject will have blood work drawn. This blood work will give the investigators a baseline value of the basic kidney function of the subject. They will then have blood work done again at 2 days and again at 3 days following the CT examination. Some patients, based on their blood work obtained at 2 and 3 days after the CT examination, will be asked to have blood work performed at 7 days after their CT examination.
Study: NCT01056497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha lipoic acid
Description: A 2 week treatment period with either oral ALA tablets or placebo tablets, followed by 30 hour hospital stay to infuse lipid or saline and to test insulin sensitivity and insulin secretion. For two weeks prior to each admission to hospital and during each hospital admission subjects will ingest 3 tablets 2 times per day with breakfast and supper, 1800mg per day
Study: NCT01514708

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimFlu-S Influenza Vaccine
Description: Suspension for injection
Study: NCT01738659

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: normal sodium diet
Description: normal sodium diet (120 mmol/daily) for 1 year
Study: NCT03856190

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fasting and plant-based nutrition
Description: The experimental intervention is divided into an initial part with periodic fasting for 7-10 days on an outpatient basis, which is followed by a build-up phase. This group part then receives a diet change with a specific normocaloric nutrition including the concept of time restricted eating (TRE, 16/8h) and according to the following criteria: 1) plant-based, 2) rich in prebiotics, 3) enriched with kitchen spices and kitchen herbs known for their anti-mycotic and anti-inflammatory potential.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Nutrition Counselling
Description: The control group receives a diet considered to be fundamentally beneficial to health in the sense of the recommendations of the German Association for Nutrition (DGE), which contain a reduced intake of arachidonic acid and, as a result, modulate an anti-inflammatory effect.
Study: NCT03517813

Intervention type: DEVICE
Intervention: Contrast-enhanced Spectral Mammography (CESM)
Description: Dual energy mammography images obtained after the administration of an intravenous contrast agent

Intervention type: DEVICE
Intervention: Contrast-enhanced Spectral Mammography (CESM)
Description: Dual energy mammography images obtained after the administration of an intravenous contrast agent
Study: NCT03377699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Description: Injection for subcutaneous (s.c., under the skin) use once daily. The total trial duration for subjects will be maximum 25 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Description: Injection for subcutaneous (s.c., under the skin) use 2-4 times daily with meals. The total trial duration for subjects will be maximum 25 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Injection for subcutaneous (s.c., under the skin) use 2-4 times daily with meals. The total trial duration for subjects will be maximum 25 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin detemir
Description: Injection for subcutaneous (s.c., under the skin) use, once daily or twice daily. The total trial duration for subjects will be maximum 25 months
Study: NCT00224887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In home nutrition counseling
Description: In home family-based behavioral counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard nutrition education curriculum
Description: video and lesson plans based on USDA Food Guide Pyramid
Study: NCT02672852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Risankizumab administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for risankizumab administered by subcutaneous injection
Study: NCT03384160

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 -Pain monitor
Description: Use of the anesthetic Mepivacaine 2% in third molar extraction and evaluation in postoperative

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 -Pain monitor
Description: Use of the anesthetic Articaine 4% in third molar extraction and evaluation in postoperative
Study: NCT01609244

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilevel therapy (somnovent ST 22, Weinmann, Hamburg, Germany)
Description: nighttime positive airway therapy for 6 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: servoventilation (Somnovent CR, Weinmann, Hamburg, Germany)
Description: nighttime positive airway therapy for 6 weeks
Study: NCT03476759

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tubal adhesiolysis
Description: 125 patients will undergo tubal adhesiolysis or tuboplasty

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVF/ICSI
Description: 125 patients will undergo IVF-ICSI procedures.
Study: NCT03625180

Intervention type: BIOLOGICAL
Intervention: NAMIC: nanofractured autologous matrix-induced chondrogenesis
Description: the NAMIC technique consists in: debridement of damaged tissue, removal of calcified cartilage with retention of healthy surrounding vertical cartilage, minimally invasive subchondral bone marrow stimulation, nanofracture (Nano FX, Arthrosurface, USA), and a posteriori protect the lesion, stabilization of the clot, and facilitate stem cell adhesion and proliferation that migrate from the bone marrow with a type I/ III collagen and elastine membrane (Cartimaix, Matricel, Germany).
Study: NCT03712059

Intervention type: DIAGNOSTIC_TEST
Intervention: FIT test and colonoscopy
Description: All included patients received FIT test and then colonoscopy, with the risk factors of CRC recorded. The diagnostic performance of predicting model (based on FIT and risk factors) and colonoscopy were compared.

Intervention type: DIAGNOSTIC_TEST
Intervention: FIT test and colonoscopy
Description: All included patients received FIT test and then colonoscopy, with the risk factors of CRC recorded. The diagnostic performance of predicting model (based on FIT and risk factors) and colonoscopy were compared.

Intervention type: DIAGNOSTIC_TEST
Intervention: Polypectomy and biopsy
Description: All included patients received polypectomy, and then biopsy is performed on the edge of resection for patients with \< 10 mm adenoma (confirmed by pathology or predicted by NBI images), with the complete resection rate of polyps being calculated.

Intervention type: DIAGNOSTIC_TEST
Intervention: Polypectomy and biopsy
Description: All included patients received polypectomy, and then biopsy is performed on the edge of resection for patients with \< 10 mm adenoma (confirmed by pathology or predicted by NBI images), with the complete resection rate of polyps being calculated.

Intervention type: DIAGNOSTIC_TEST
Intervention: Classification
Description: Pathology of polyps is classified by endoscopists through NICE principle and the performance of classification between endoscopists and computer is compared.
Study: NCT02817880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tsDCS
Study: NCT00541242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost 0.03% eye drops
Description: Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of bimatoprost 0.03% 1 drop every evening for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.005% eye drops
Description: Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of latanoprost 0.005% 1 drop every evening for 12 weeks
Study: NCT02203266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Feedback on the patient's own inhaler use, with personalized information on the patients technique and timing of use of the diskus inhaler as recorded on the INCA device will be provided to patients in the feedback group after 1,2 and 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Feedback on the patient's own inhaler technique as observed by pharmacist and education to support best use will be provided to patients in the demonstration group after 1,2 and 6 months.
Study: NCT02577536

Intervention type: OTHER
Intervention: No Interventions
Description: No Interventions will be conducted under this study.
Study: NCT03669588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-113
Description: Intravenous administration of ARGX-113

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration of placebo
Study: NCT03907644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Alternating Current Stimulation (tACS)
Description: The tACS stimulator delivers very low (2mAmp) current with surface electrodes to the skull.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Alternating Current Stimulation (tACS)
Description: The tACS stimulator delivers very low (2mAmp) current with surface electrodes to the skull.
Study: NCT02157389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of a pharmacological placebo
Study: NCT02725021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Against Tobacco school-based intervention by medical students
Study: NCT04546425

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20-valent pneumococcal conjugate vaccine
Description: 20-valent pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 13-valent pneumococcal conjugate vaccine
Study: NCT00564746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A single 10 milligram (50 microcurie) oral dose of [14C]SB-681323
Description: \[14C\] SB-681323 oral solution, is available as a powder which will be made into a solution of 0.1 milligram/milliliter (0.5 microcurie) \[14C\] SB-681323 in dextrose and water for injection on the day prior to dosing.~For a 10 milligram/50 microcurie oral dose of \[14C\]SB-681323, 100 milliliters of 0.1 milligram/milliliter (0.5 microcurie/milliliter \[14C\] SB-681323 oral solution will be dosed.
Study: NCT01461811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nelfilcon A toric contact lenses (with comfort additives)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelfilcon A toric contact lenses
Study: NCT03865927

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: see Arm/Group description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GKT137831
Description: GKT137831 is a NOX enzyme inhibitor
Study: NCT04116892

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the Cover group
Description: The internal limiting membrane around the MH was left to cover the hole
Study: NCT00953030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COACH

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RealAge
Study: NCT04105179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zimmer NexGen LPS-Flex
Description: Patients will be randomly assigned to 1 of 2 devices

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smith & Nephew Journey II
Description: Patients will be randomly assigned to 1 of 2 devices
Study: NCT02460016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK0529
Description: AK0529 pellets for oral administration
Study: NCT03905733

Intervention type: DEVICE
Intervention: Optiflow
Description: supply of oxygen at 2 L / min/ kg through Optiflow
Study: NCT01883895

Intervention type: DEVICE
Group type: OTHER
Intervention: Forgionei-Barber pressure-pain stimulator
Description: Pain testing will be conducted using a Forgioni-Barber pressure-pain stimulator to deliver 3000-gm force to the middle digit of the non-dominant middle finger for up to 120 seconds. During stimulation, subjects will press a button attached to a timer when the pressure stimulus first becomes painful (pain threshold) and will also rate their perceived pain intensity using a 0-100 numeric pain rating scale at 20 second intervals during the 2 minute exposure to the pressure stimulus. This validated protocol has been used in previous research by investigators in this study. This will be used for both exercise sessions and the control session. Forgionei-Barber pressure-pain stimulator will be used.

Intervention type: OTHER
Group type: OTHER
Intervention: Concentric Exercise
Description: Concentric testing will utilize a dumbbell with elbow flexion exercise. Subjects will perform 5 sets of 20 reps at 30% MVC. Pain testing will be conducted using a Forgionei-Barber pressure-pain stimulator immediately before and after the exercise.

Intervention type: OTHER
Group type: OTHER
Intervention: isometric exercise
Description: When undergoing isometric exercise, subjects will perform 5 sets of sustained muscle contraction for 65 seconds using a hand-grip dynamometer. Pain testing will be conducted using a Forgionei-Barber pressure-pain stimulator immediately before and after the exercise.
Study: NCT02171000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS
Description: 150 mg capsules, b.i.d, 7 days
Study: NCT01053455

Intervention type: DEVICE
Intervention: SiPAP
Description: biphasic CPAP (SiPAP) to be alternated in 1 hour blocks with NCPAP

Intervention type: DEVICE
Intervention: SiPAP
Description: biphasic CPAP (SiPAP) to be alternated in 1 hour blocks with NCPAP
Study: NCT00483535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW273225
Description: GW273225 will be available as 25 milligram tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COC
Description: COC will consist of Microgynon 30 which is available as ethinylestradiol 30 micrograms/levonorgestrel 150 micrograms beige color, sugar-coated tablets.
Study: NCT02785198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive knee extensor machine
Description: The passive training machine, moves both legs from flexion to extension and back, 60 times per minute in 1 hour, 3 times per week. ROM is 60 degrees
Study: NCT00973258

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Each subject in the nutritional intervention group is provided with a commercial liquid formula (Fortisip Multi Fibre, Nutricia), which should be taken every evening for a period of 24 weeks. Subjects are also given one capsule of iron and folate supplement (Sangobion, Merck; consisting of 1 mg folate and 29mg iron), one capsule of Vitamin B6 and vitamin B12 supplement (Neuroforte; consisting of 200mcg B12 and 200mg vit B6) and one tablet of Caltrate with Vitamin D (consisting of 200 IU vitamin D and 600 mg of calcium) for a duration of 24 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: The exercise intervention group comprises a combination of 2 types of exercise: resistance exercise and in-balance exercise. Key components in both programs are balance and strength, because these are the most prominent domains that should be addressed in at risk frail elderly. The first program is administered in the first 6-week, and then followed by the second program for the next 6-week of intervention period. Both exercise programmes are tailored to the functional needs of the participants, maintaining a moderate intensity that focuses on long-term sustainability and enjoyment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: The proposed cognitive training intervention program comprises:~1. Reasoning training focusing on inductive reasoning, the ability to solve problems that follow a serial pattern and manifest in executive functioning.~2. Memory training focusing on verbal episodic memory, which deals with acquisition and retrieval of information acquired in a particular place at a particular time.~3. Speed training focusing on visual search and the ability to identify and locate visual information quickly in a divided attention format, with and without distractors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined
Description: Nutritional Intervention + Physical Exercise + Cognitive Training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive their usual diet and placeboes.
Study: NCT03308552

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: SIB-IMRT
Description: PTV:50.4Gy/28f, PGTV:59.92Gy/28f

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SIB-IMRT
Description: PTV:50.4Gy/28f, PGTV:59.92Gy/28f

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 45-50 mg/m2, once a week, concurrent with radiotherapy for 5-6weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum-Based Drug
Description: Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 150mg/m2 on day1,every 3 weeks, 4 cycles, 1-3 months after completion of radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 150mg/m2 on day1,every 3 weeks, 4 cycles, 1-3 months after completion of radiotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Platinum-Based Drug
Description: Nedaplatin or Lobaplatin or Cisplatin, 50-80mg/m2 on day1 (Lobaplatin 50mg on day 1),every 3 weeks, 4 cycles, 1 month after completion of radiotherapy
Study: NCT04116892

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the Fill group
Description: The internal limiting membrane around the MH was left to fill the hole

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the peeling group
Description: the internal limiting membrane was discarded
Study: NCT03047395

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab 150 mg administered by subcutaneous injection every 12 weeks.
Study: NCT00941967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally.
Study: NCT03262259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GSDG multi-component intervention
Description: Multi-component intervention, including screening and brief intervention, other evidence-based interventions, and novel or partially tested interventions that warrant further evaluation.
Study: NCT04296266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alda-341
Description: Dietary supplement d-limonene orally administered as a drug.